2011
DOI: 10.1016/j.spinee.2011.06.001
|View full text |Cite
|
Sign up to set email alerts
|

A challenge to integrity in spine publications: years of living dangerously with the promotion of bone growth factors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
69
0
1

Year Published

2011
2011
2017
2017

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 98 publications
(70 citation statements)
references
References 27 publications
0
69
0
1
Order By: Relevance
“…Physician-industry relationships can create a risk of bias in research study designs, experimental technique, and result interpretation and may affect treatment decisions in patient care [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] . However, physicians are in the best position to provide valuable innovations in design and safety that are mutually beneficial for patients, physicians, and industry 1 .…”
mentioning
confidence: 99%
“…Physician-industry relationships can create a risk of bias in research study designs, experimental technique, and result interpretation and may affect treatment decisions in patient care [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] . However, physicians are in the best position to provide valuable innovations in design and safety that are mutually beneficial for patients, physicians, and industry 1 .…”
mentioning
confidence: 99%
“…Further study is needed as to whether there are editoriallevel conflicts in disc replacement studies. Recent actions taken by spine journal editors on other topics in spine surgery, including creating special embargoed issues with multiple redundant commentaries, demonstrate the ability of journal editors to advocate about specific issues [66,67].…”
Section: Financial Conflict Of Interestmentioning
confidence: 99%
“…However, in 2011, Carragee et al [45,46] reviewed the complications associated with the use of BMP-2 in spine surgery. They identified a significant number of industry-sponsored trials (N = 13) "remarkable for the complete absence of reported rhBMP-2 related clinical events".…”
Section: Graftmentioning
confidence: 99%